Z12.2 Insurance Policy Changes

ICD-10 Z12.2 is officially defined as "Encounter for screening for malignant neoplasm of respiratory organs." code Z12.2 is referenced in 6 tracked payer policy changes from Excellus BlueCross BlueShield, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z12.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Oct 22, 2026Medium impact
Molecular Testing in the Management of Pulmonary Nodules 2.02.58
Policy 2.02.58 considers molecular testing for undiagnosed pulmonary nodules investigational in all circumstances, including plasma-based proteomic screening, gene expression of bronchial brushings or nasal swabs, and flow cytometry of sputum. The policy names CyPath Lung, EarlyCDT Lung, LungLB, Nodify CDT, Nodify XL2, OncobiotaLUNG, ReVeal Lung Nodule Characterization, PAULA's Test, Percepta Genomic Sequencing Classifier and Percepta Nasal Swab as investigational tests. The current effective date is October 22, 2026, and the 10/22/26 annual review left the policy intent unchanged.
Aetna · Identified Nov 2, 2026Medium impact
Exhaled Breath Tests (CPB 0691, reviewed 2026-10-27)
Aetna reviewed its clinical policy on exhaled breath tests (CPB 0691) on 2026-10-27, and the text does not state a new effective date or a specific new requirement. It sets out which breath tests Aetna treats as medically necessary: hydrogen breath testing for lactose intolerance or small intestinal bacterial overgrowth, and exhaled nitric oxide for asthma in members aged 5 and older. Other breath tests, including breath condensate pH, gastric emptying breath tests and exhaled volatile organic compound tests, are listed as not covered or experimental for the indications named.
Aetna · Identified Aug 19, 2026Medium impact
Lung Cancer Screening (CPB 0380, reviewed 2026-05-28)
Aetna covers annual low-dose CT (LDCT) lung cancer screening, CPT 71271, for current or former smokers ages 50 to 80 with a 20 pack-year or more smoking history, and former smokers must have quit within the past 15 years. Annual LDCT is also covered for surveillance of non-small cell lung cancer, starting 2 years after definitive treatment, using CPT 71250. Artificial intelligence-based imaging, computer-aided detection for chest radiographs, PET for lung cancer screening, and LDCT screening for other indications such as asbestos-exposed individuals are considered experimental, investigational or unproven.
Aetna · Identified Aug 17, 2026Medium impact
ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)
Aetna considers the ADAMTS13 assay medically necessary for assessing prognosis in persons with thrombotic thrombocytopenic purpura (TTP), and for distinguishing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA, also called transplant-associated TMA) from TTP in persons with overlapping features when the test will be used to inform treatment. Aetna considers the assay experimental, investigational, or unproven for the uses it lists because of insufficient evidence, including sepsis-associated thrombotic microangiopathy, hemolytic uremic syndrome, acute myelogenous leukemia, colorectal cancer survival, COVID-19, cerebral infarction, and ADAMTS13 mutation testing for non-cirrhotic portal hypertension.
Aetna · Identified Aug 14, 2026Medium impact
Single Photon Emission Computed Tomography (SPECT) (CPB 0376, reviewed 2026-05-28)
Aetna's Clinical Policy Bulletin 0376 sets the coverage rules for single photon emission computed tomography (SPECT). Non-cardiac SPECT is considered medically necessary for a list of indications, including osteomyelitis, distinguishing bone from soft tissue infection, pulmonary embolism by SPECT ventilation/perfusion scintigraphy, distinguishing Parkinson's disease from essential tremor using DaTSCAN, localization of abscesses, lymphoma and necrosis differentiation, neuroendocrine tumor diagnosis and staging, presurgical ictal detection of seizure focus in epilepsy in place of PET, and thyroid cancer iodine imaging. SPECT for coronary artery disease diagnosis and prognosis is considered medically necessary, except as outlined in the policy's exclusion criteria. SPECT for a list of other uses, including Alzheimer's disease and dementia, attention deficit/hyperactivity disorder, autism, schizophrenia, stroke, and absolute quantitation of myocardial blood flow, is considered experimental, investigational or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Screening for Lung Cancer Using Computed Tomography (CT) Scanning
This policy was last reviewed 06/24/2024 with no changes. Low-dose computed tomography (CT) scanning, no more frequently than annually, may be considered medically necessary as a screening technique for lung cancer in individuals who are between 50 and 80 years of age with a history of cigarette smoking of at least 20 pack-years. Former smokers must have quit within the previous 15 years. Low-dose CT scanning is investigational as a screening technique for lung cancer in all other situations, and screening does not apply to individuals with signs or symptoms of lung disease.

Watch Z12.2

Get one email when a payer policy names Z12.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z12.2?

There are 6 tracked policy changes affecting code Z12.2, including updates from Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z12.2?

Payers that have issued tracked updates for code Z12.2 include: Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code Z12.2 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z12.2. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z12.2?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Molecular Testing in the Management of Pulmonary Nodules 2.02.58

Exhaled Breath Tests (CPB 0691, reviewed 2026-10-27)

Lung Cancer Screening (CPB 0380, reviewed 2026-05-28)

ADAMTS13 Assay for Thrombotic Thrombocytopenic Purpura (TTP) (CPB 0780, reviewed 2026-04-27)

Single Photon Emission Computed Tomography (SPECT) (CPB 0376, reviewed 2026-05-28)

Screening for Lung Cancer Using Computed Tomography (CT) Scanning

What insurance policy changes affect code Z12.2?

Which payers have updated policy for code Z12.2?

How do I get notified when code Z12.2 policy changes?

Why do payers change policies for code Z12.2?